A new drug that treats relapsing forms of multiple sclerosis will soon be available in the United States. The FDA has approved the use of Mayzent.
It is the first and only oral drug specifically designed to treat active secondary, progressive MS in adults.
The condition is characterized by neurological symptoms that significantly worsen over time.
The Swiss drug company Novartis says the list price for that drug will be $88,000 per year.